Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644· Phase 3· SystImmune Inc.· Source
Contact: Trenis Palmer
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782· Phase 2· Verastem, Inc.· Source
Contact: Matthew Nguyen
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559· Phase 2· Verastem, Inc.· Source
Contact: Trenis Palmer
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738· Phase 1/2· Orion Corporation, Orion Pharma· Source
Contact: David Berz, MD
Recruiting
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
NCT07306559· Phase 1· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298· Phase 1/2· Pfizer· Source
Recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
NCT07321106· Phase 1· Cartography Biosciences· Source
Contact: Myo Zaw
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Incyte Corporation· Source
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432· Phase 1/2· Vironexis Biotherapeutics Inc.· Source
Contact: Myo Zaw
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source
Contact: David Berz, Site 0283
Active, not recruiting
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066· Phase 1· SystImmune Inc.· Source
Active, not recruiting
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT06966453· Phase 1/2· Pfizer· Source
Recruiting
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06533579· Phase 1/2· Vironexis Biotherapeutics Inc.· Source
Contact: Myo Zaw
Recruiting
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242· Phase 1· SystImmune Inc.· Source
Contact: Trenis Palmer, PhD
Recruiting
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
NCT06806033· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522· Phase 2· Amgen· Source
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768· Phase 1/2· Daiichi Sankyo· Source
Active, not recruiting
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721· Phase 3· Amgen· Source
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT06476808· Phase 1· Bristol-Myers Squibb· Source
Contact: David Berz, Site 0006
Active, not recruiting
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222· Phase 2· BioNTech SE· Source
Active, not recruiting
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209· Phase 2· BioNTech SE· Source
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357· Phase 1/2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064· Phase 1/2· Daiichi Sankyo· Source
Active, not recruiting
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774· Phase 3· Amgen· Source
Active, not recruiting
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574· Phase 3· Boehringer Ingelheim· Source
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821· Phase 3· BeOne Medicines· Source
Active, not recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· Phase 3· Summit Therapeutics· Source
Recruiting
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
NCT06119685· Phase 1/2· Indapta Therapeutics, INC.· Source
Contact: Myo Zaw
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936· Phase 3· Hoffmann-La Roche· Source
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058· Phase 2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
Phase III Study of AK112 for NSCLC Patients
NCT06396065· Phase 3· Summit Therapeutics· Source
Active, not recruiting
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370· Phase 1/2· BeiGene· Source
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045· Phase 1· Jazz Pharmaceuticals· Source
Active, not recruiting
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT05032040· Phase 2· Xencor, Inc.· Source
Active, not recruiting
Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT05238922· Phase 1· Incyte Corporation· Source
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· Phase 3· BeOne Medicines· Source
Recruiting
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
NCT04486833· Phase 1/2· Genprex, Inc.· Source
Contact: Kristi Okino
Recruiting
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804· Phase 1· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766· Phase 1/2· Inhibrx Biosciences, Inc· Source
Contact: Myo Zaw
Recruiting
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933· Phase 1· Inhibrx Biosciences, Inc· Source
Contact: Carla Collier